Department of Human Anatomy, Medical University of Lublin, 20-090 Lublin, Poland.
Department of Plastic, Reconstructive and Maxillary Surgery, Central Clinical Hospital MSWiA, 02-507 Warsaw, Poland.
Int J Mol Sci. 2022 Mar 2;23(5):2745. doi: 10.3390/ijms23052745.
Mesenchymal stem cells (MSCs) are considered to be a powerful tool in the treatment of various diseases. Scientists are particularly interested in the possibility of using MSCs in cancer therapy. The research carried out so far has shown that MSCs possess both potential pro-oncogenic and anti-oncogenic properties. It has been confirmed that MSCs can regulate tumor cell growth through a paracrine mechanism, and molecules secreted by MSCs can promote or block a variety of signaling pathways. These findings may be crucial in the development of new MSC-based cell therapeutic strategies. The abilities of MSCs such as tumor tropism, deep migration and immune evasion have evoked considerable interest in their use as tumor-specific vectors for small-molecule anticancer agents. Studies have shown that MSCs can be successfully loaded with chemotherapeutic drugs such as gemcitabine and paclitaxel, and can release them at the site of primary and metastatic neoplasms. The inhibitory effect of MSCs loaded with anti-cancer agents on the proliferation of cancer cells has also been observed. However, not all known chemotherapeutic agents can be used in this approach, mainly due to their cytotoxicity towards MSCs and insufficient loading and release capacity. Quinazoline derivatives appear to be an attractive choice for this therapeutic solution due to their biological and pharmacological properties. There are several quinazolines that have been approved for clinical use as anticancer drugs by the US Food and Drug Administration (FDA). It gives hope that the synthesis of new quinazoline derivatives and the development of methods of their application may contribute to the establishment of highly effective therapies for oncological patients. However, a deeper understanding of interactions between MSCs and tumor cells, and the exploration of the possibilities of using quinazoline derivatives in MSC-based therapy is necessary to achieve this goal. The aim of this review is to discuss the prospects for using MSC-based cell therapy in cancer treatment and the potential use of quinazolines in this procedure.
间充质干细胞(MSCs)被认为是治疗各种疾病的有力工具。科学家们特别感兴趣的是将 MSCs 应用于癌症治疗的可能性。迄今为止的研究表明,MSCs 具有潜在的致癌和抑癌特性。已经证实,MSCs 可以通过旁分泌机制调节肿瘤细胞的生长,MSCs 分泌的分子可以促进或阻断多种信号通路。这些发现可能对开发基于 MSC 的新型细胞治疗策略至关重要。MSCs 具有肿瘤趋向性、深部迁移和免疫逃避等能力,这引起了人们对其作为小分子抗癌药物肿瘤特异性载体的极大兴趣。研究表明,MSCs 可以成功负载吉西他滨和紫杉醇等化疗药物,并在原发性和转移性肿瘤部位释放它们。负载抗癌药物的 MSCs 对癌细胞增殖的抑制作用也得到了观察。然而,并非所有已知的化疗药物都可以用于这种方法,主要是因为它们对 MSCs 的细胞毒性以及负载和释放能力不足。由于其生物学和药理学特性,喹唑啉衍生物似乎是这种治疗方法的一个有吸引力的选择。有几种喹唑啉已被美国食品和药物管理局(FDA)批准作为抗癌药物用于临床。这给人希望,即合成新的喹唑啉衍生物并开发其应用方法可能有助于为肿瘤患者建立高效的治疗方法。然而,为了实现这一目标,有必要更深入地了解 MSCs 与肿瘤细胞之间的相互作用,并探索喹唑啉衍生物在 MSC 为基础的治疗中的应用可能性。本文的目的是讨论基于 MSC 的细胞治疗在癌症治疗中的应用前景以及喹唑啉在该过程中的潜在应用。
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2018-5-25
Anticancer Agents Med Chem. 2021
Eur J Med Chem. 2021-2-5
Int J Nanomedicine. 2021
Expert Opin Ther Pat. 2015-7
Front Cell Dev Biol. 2025-5-8
Adv Pharm Bull. 2024-10
Cancers (Basel). 2024-8-20
Breast Cancer (Dove Med Press). 2024-7-2
Front Bioeng Biotechnol. 2020-7-23
Curr Opin Pharmacol. 2020-8
Anticancer Res. 2020-6